Experiment Number: K10262 **Route:** Intravenous, Gavage

Species/Strain: Rats/Fischer 344/N

Toxicokinetics Data Summary

Compound: Isoeugenol/ **Analyte:** Isoeugenol

CAS Number: 97-54-1

Request Date: 7/11/2023 Request Time: 10:03:16

Lab: RTI

Male

Treatment Group (mg/kg)

	11-catilient 61-cab (1116) (18)				
	17 IV Plasma ^{a,c}	17 Gavage Plasmab	35 Gavage Plasmab	140 Gavage Plasma	
C_0min_pred (ug/mL)	10.5 ± 1.2				
Cmax_obs (ug/mL)		0.192 ± 0.022	1.02 ± 0.41	2.06 ± 0.73	
Tmax_obs (minute)		10	20	20	
Alpha (min ⁻¹)	0.0869 ± 0.0064				
Alpha Half-life (min)	7.98 ± 0.59				
Beta (min ⁻¹)	0.0100 ± 0.0009				
Beta Half-life (min)	69.1 ± 6.2				
CI (mL min ⁻¹ kg ⁻¹)	110 ± 2				
Cl1_F (mL*min ⁻¹ *kg ⁻¹)		1062 ± 74	755 ± 65	499 ± 35	
V1 (L/kg)	11.0 ± 1.0				
AUC_0-T (ug/mL*min)	131 ± 3	16.0 ± 1.1	92.7 ± 8.0	280 ± 19	
AUCinf_pred (ug mL ⁻¹ min)	146 ± 10				
F (percent)		17 ± 2			

Experiment Number: K10262 **Route:** Intravenous, Gavage

Species/Strain: Rats/Fischer 344/N

Toxicokinetics Data Summary

Compound: Isoeugenol/ Analyte: Isoeugenol

CAS Number: 97-54-1

Request Date: 7/11/2023 **Request Time:** 10:03:16

Lab: RTI

Female

Treatment Group (mg/kg)

rreatment Group (mg/kg/						
	17 IV Plasma ^{a,c}	17 Gavage Plasmab	35 Gavage Plasmab	140 Gavage Plasma ^b		
C_0min_pred (ug/mL)	10.6 ± 0.9					
Cmax_obs (ug/mL)		0.364 ± 0.103	1.82 ± 0.88	5.91 ± 2.28		
Tmax_obs (min)		10	2	5		
Alpha (min ⁻¹)	0.0920 ± 0.0052					
Alpha Half-life (min)	7.54 ± 0.42					
Beta (min ⁻¹)	0.00872 ± 0.00044					
Beta Half-life (min)	79.5 ± 4.1					
CI (mL min ⁻¹ kg ⁻¹)	105 ± 2					
Cl1_F (mL*min ⁻¹ *kg ⁻¹)		564 ± 53	455 ± 29	339 ± 13		
V1 (L/kg)	12.0 ± 0.7					
AUC_0-T (ug/mL*min)	139 ± 3	30.1 ± 2.8	154 ± 10	413 ± 16		
AUCinf_pred (ug mL-1min)	156 ± 7					
F (percent)	11 ± 2					

Experiment Number: K10262 **Route:** Intravenous, Gavage

Species/Strain: Rats/Fischer 344/N

Toxicokinetics Data Summary
Compound: Isoeugenol/ Analyte: Isoeugenol

CAS Number: 97-54-1

Request Date: 7/11/2023 **Request Time:** 10:03:16

Lab: RTI

LEGEND

MODELING SOFTWARE PROC NLIN

MODELING METHOD & BEST FIT MODEL

^aA nonlinear least-squares fitting program SAS PROC NLIN, SAS Institute, Inc., Cary, NC, Elimination of IEG was modeled for both species using a biphasic exponential equation C(t) = Aoe^{-alpha*t} + Boe^{-beta*t} () where C(t) is the plasma IEG concentration at any post-administration time (t), alpha and beta are the rate constants (min-1) obtained from the fit, Ao and Bo are the intercepts on the ordinate (concentration) axis of the extrapolated initial and terminal phases, respectively. weighting factor of [mean plasma IEG concentration]-2

^bManual, Plasma MEG concentration-versus-time profiles for both species were characterized by an early absorption phase followed by at least one secondary peak which prevented estimation of elimination rates. No modeling was done on the oral gavage data. Parameters were calculated using observed values.

EXCEPTION

^cCl is total clearance, V1 represents Vapp

ANALYTE

Isoeugenol

TK PARAMETERS

C_Omin_pred = Fitted plasma concentration at time zero (IV only)

Cmax_obs = Observed or Predicted Maximum plasma (or tissue) concentration

Tmax_obs = Time at which Cmax predicted or observed occurs

Alpha = Hybrid rate constant of the alpha phase

Alpha Half-life = Half-life for the alpha phase

Beta = Hybrid rate constant of the beta phase

Beta Half-life = Half-life for the beta phase

CI = Clearance, includes total clearance

Cl1_F = Apparent clearance of the central compartment, also Cl_F for gavage groups in non-compartmental model

Experiment Number: K10262 Route: Intravenous, Gavage Species/Strain: Rats/Fischer 344/N

Toxicokinetics Data Summary Compound: Isoeugenol/Analyte: Isoeugenol **CAS Number:** 97-54-1

Request Time: 10:03:16

Request Date: 7/11/2023

Lab: RTI

TK PARAMETERS (cont'd)

V1 = Volume of distribution of the central compartment, includes Vd and V volume of distribution, Vz apparent volume of distribution NCA, Vapp apparent volume of distribution for intravenous studies

AUC_0-T = Area under the plasma concentration versus time curve, AUC, from time ti (initial) to tf (final), AUClast AUCinf pred = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity F = Bioavailability, absolute bioavailability

TK PARAMETERS PROTOCOL

ANALYSIS METHOD

Plasma Isoeugenol (IEG) concentrations were measured using a validated gas chromatography-mass spectrometry (GC-MS) method. Plasma level of detection (LOD) is 0.0009 ug/mL, the limit of quantitation (LOQ) is 0.0031 ug/mL and the plasma experimental level of detection ELOQ is 0.015 ug/mL. All IV dosed rat IEG concentrations were above the LOD and only 3 out of 84 measurements fell between the LOD and the ELOQ. Toxicokinetic parameter estimates following intravenous administration were derived only from those plasma IEG measurements that were above the ELOQ.

TK_INTRAVENOUS PLASMA

17 mg/kg Male and Female

Animals were weighed the morning of dosing for calculation of the dosing volume. Non-fasted rats were given a single bolus intravenous injection through a Silastic catheter surgically implanted by the supplier followed by approximately 0.5 mL of heparinized saline solution (10 units/mL). Animals were anesthetized with approximately 70 percent CO2-30 percent O2 and blood was collected from rats via the retroorbital sinus using heparinized micro-hematocrit capillary tubes. Rats were bled twice with three rats/sex/time point for 14 time points.

Experiment Number: K10262 Route: Intravenous, Gavage

Toxicokinetics Data Summary Compound: Isoeugenol/Analyte: Isoeugenol **CAS Number:** 97-54-1

Species/Strain: Rats/Fischer 344/N

Lab: RTI

Request Date: 7/11/2023

Request Time: 10:03:16

TK PARAMETERS PROTOCOL (cont'd)

TK_GAVAGE PLASMA

17 mg/kg, 35 mg/kg, 140 mg/kg Male and Female

Animals were weighed the day prior to dosing for calculation of the dosing volume and given a single gavage dose the next morning. Animals were anesthetized with approximately 70 percent CO2-30 percent O2 and blood was collected from rats via the retroorbital sinus using heparinized micro-hematocrit capillary tubes. Rats were bled twice with three rats/sex/time point for 14 time points.